G1 Therapeutics Announces Expansion of Development Programs


G1 Therapeutics announced today the expansion of its pipeline of novel cancer therapies with initiation of three development programs in breast cancer. G1 is enrolling a Phase 2 study of its intravenous CDK4/6 inhibitor trilaciclib for the treatment of triple-negative breast cancer (TNBC), and a Phase 1b/2a study of its oral CDK4/6 inhibitor G1T38 for the treatment of ER+, HER2-... Continue

Medicines Company Announces Top-Line Inclisiran Data


The Medicines Company today announced positive top-line results from the interim analysis with Day 180 follow-up for all 501 patients enrolled in the ongoing ORION-1 Phase 2 study of inclisiran, its investigational, first-in-class PCSK9 synthesis inhibitor Continue